1
|
Akagun T, Yazici H, Caliskan Y, Ozluk Y, Sahin S, Turkmen A, Kılıcaslan I, Sever MS. The effect of histopathologic and clinical features on allograft survival in renal transplant patients with antibody-mediated rejection. Ren Fail 2016; 39:19-25. [PMID: 27776435 PMCID: PMC6014486 DOI: 10.1080/0886022x.2016.1244073] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Background: Antibody-mediated rejection is a frequent cause of graft failure; however, prognostic indications of this complication have not been well defined. The aim of this study was to evaluate the association of histopathological and clinical features and to determine the effect of these findings on allograft survival in patients with AMR. Methods: Fifty-two patients suffered from AMR (30 male; mean age 39 ± 11 years) were included in the study. Data were investigated retrospectively and graft survival was analyzed. All transplant biopsies were evaluated according to Banff 2009 classification. Results: Of the 52 cases, 45 were transplanted from living-donors. Twenty-one patients were diagnosed in the first 3-months after transplantation. Graft survival was 65% at 12 months and 54% at 36 months. Mean serum creatinine at time of biopsy was 3.8 ± 3.6 mg/dL. Thirty-five of the 52 cases showed diffuse C4d positivity, 12 cases showed focal and 5 remained C4d negative. One of the patients died, 13 experienced graft loss and 38 survived with functioning grafts. Serum creatinine levels at time of biopsy were correlated with graft survival (p = .021: OR = 1.10: 95 % CI = 1.015–1.199). In terms of the impact of pathological findings; tubulitis (p=.007: OR = 2.62: 95 % CI = 1.301–5.276), intimal arteritis (p=.017: OR = 2.85: 95% CI = 1.205–6.744) and interstitial infiltration (p=.004: OR = 3.37: 95% CI = 1.465–7.752) were associated with graft survival. Conclusions: Serum creatinine at time of biopsy, tubulitis, intimal arteritis and interstitial infiltration were significantly associated with graft survival. Antibody-mediated rejection is associated with reduced long-term graft survival.
Collapse
Affiliation(s)
- Tulin Akagun
- a Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey
| | - Halil Yazici
- a Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey
| | - Yasar Caliskan
- a Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey
| | - Yasemin Ozluk
- b Department of Pathology, Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey
| | - Sevgi Sahin
- c Nephrology Clinic , Acibadem Atakent Hospital , Istanbul , Turkey
| | - Aydin Turkmen
- a Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey
| | - Isın Kılıcaslan
- b Department of Pathology, Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey
| | - Mehmet Sukru Sever
- a Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey
| |
Collapse
|
2
|
Devadass CW, Vanikar AV, Nigam LK, Kanodia KV, Patel RD, Vinay KS, Patel HV. Evaluation of Renal Allograft Biopsies for Graft Dysfunction and Relevance of C4d Staining in Antibody Mediated Rejection. J Clin Diagn Res 2016; 10:EC11-5. [PMID: 27134877 DOI: 10.7860/jcdr/2016/16339.7433] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Accepted: 01/05/2016] [Indexed: 11/24/2022]
Abstract
INTRODUCTION Biopsy remains gold standard for diagnosis of Graft Dysfunction (GD). It guides clinical management, provides valuable insights into pathogenesis of early and late allograft injury and is indispensable for distinguishing rejection from non- rejection causes of GD. AIM The primary aim of the study was to evaluate the diverse histomorphological lesions in renal allograft biopsy (RAB). Further, we determined the frequency of peritubular capillary (PTC) C4d positivity and its correlation with microvascular inflammation in Antibody Mediated Rejection (AMR). MATERIALS AND METHODS This was a prospective study on RAB over a period of 2 months. Histopathological evaluation was undertaken as per revised Banff'13 schema. Immunohistochemistry was performed to detect PTC C4d deposition. RESULTS Sixty five diagnostic biopsies were evaluated. Mean patient age was 34 years and males were predominant. The time interval between graft biopsy and transplantation ranged from 5 days to 8 years, with 52.3% biopsies belonging to period of ≤ 6 months post-transplant. Immune injuries were observed in 40 biopsies out of which AMR was observed in 35 biopsies. Calcineurin inhibitor toxicity (CNI Toxicity) was the second commonest cause observed in 12 biopsies and other lesions including de novo glomerulopathies were observed in the remaining biopsies. The sensitivity of C4d in detecting acute AMR was 55% and chronic AMR was 23.5. CONCLUSION AMR and CNI Toxicity account for majority of graft dysfunction. C4d is not as sensitive a marker of AMR, as was initially thought. Higher proportion of moderate microvascular inflammation is found in diffuse C4d positive cases compared to focal C4d positive cases.
Collapse
Affiliation(s)
- Clement Wilfred Devadass
- Associate Professor, Department of Pathology, M.S Ramaiah Medical College and Hospitals , MSRIT Post, MSRNagar, Bangalore, India
| | - Aruna Vishwanth Vanikar
- ICMR Mentor and Guide, Professor & Head, Department of Pathology, Lab Medicine, Tranfusion Services & Immunohematology, Institute of Kidney Diseases and Research Centre & DR. H.L Trivedi Institute of Transplantation Sciences , B.J. Medical College & Civil Hospital Campus, Asarwa, Gujarat, India
| | - Lovelesh Kumar Nigam
- Assistant Professor (Junior Nephropathologist), Department of Pathology, Lab Medicine, Tranfusion Services & Immunohematology, Institute of Kidney Diseases and Research Centre & DR. H.L Trivedi Institute of Transplantation Sciences , B.J. Medical College & Civil Hospital Campus, Asarwa, Gujarat, India
| | - Kamal Vinod Kanodia
- Professor (Senior Nephropathologist), Department of Pathology, Lab Medicine, Tranfusion Services & Immunohematology, Institute of Kidney Diseases and Research Centre & DR. H.L Trivedi Institute of Transplantation Sciences , B.J. Medical College & Civil Hospital Campus, Asarwa, Gujarat, India
| | - Rashmi Dalsukhbhai Patel
- Professor (Senior Nephropathologist), Department of Pathology, Lab Medicine, Tranfusion Services & Immunohematology, Institute of Kidney Diseases and Research Centre & DR. H.L Trivedi Institute of Transplantation Sciences , B.J. Medical College & Civil Hospital Campus, Asarwa, Gujarat, India
| | - Kyasakkala Sannaboraiah Vinay
- PDCC Fellow, Department of Pathology, Lab Medicine, Tranfusion Services & Immunohematology, Institute of Kidney Diseases and Research Centre & DR. H.L Trivedi Institute of Transplantation Sciences , B.J. Medical College & Civil Hospital Campus, Asarwa, Gujarat, India
| | - Himanshu V Patel
- Professor, Department of Nephrology, Institute of Kidney Diseases and Research Centre & DR. H.L Trivedi Institute of Transplantation Sciences , B.J. Medical College & Civil Hospital Campus, Asarwa, Gujarat, India
| |
Collapse
|
3
|
Valenzuela NM, Reed EF. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol 2014; 1034:41-70. [PMID: 23775730 DOI: 10.1007/978-1-62703-493-7_2] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Until recently, allograft rejection was thought to be mediated primarily by alloreactive T cells. Consequently, immunosuppressive approaches focused on inhibition of T cell activation. While short-term graft survival has significantly improved and rejection rates have dropped, acute rejection has not been eliminated and chronic rejection remains the major threat to long-term graft survival. Increased attention to humoral immunity in experimental systems and in the clinic has revealed that donor specific antibodies (DSA) can mediate and promote acute and chronic rejection. Herein, we detail the effects of alloantibody, particularly HLA antibody, binding to graft vascular and other cells, and briefly summarize the experimental methods used to assess such outcomes.
Collapse
Affiliation(s)
- Nicole M Valenzuela
- Department of Pathology and Laboratory Medicine, UCLA Immunogenetics Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | | |
Collapse
|
4
|
Ravindra K, Haeberle M, Levin LS, Ildstad ST. Immunology of vascularized composite allotransplantation: a primer for hand surgeons. J Hand Surg Am 2012; 37:842-50. [PMID: 22464235 DOI: 10.1016/j.jhsa.2012.01.042] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2011] [Accepted: 01/31/2012] [Indexed: 02/02/2023]
Abstract
Vascularized composite allotransplantation is a recent innovation in the fields of transplantation surgery, plastic and reconstructive surgery, and orthopedic surgery. The success of hand and face transplantation has been based on extensive experience in solid organ transplantation. Advances in understanding the immunology of transplantation have had a major role in achieving excellent results in this new field. The purpose of this article is to introduce the basics of human immunology (innate and adaptive systems) and the immunological basis of human transplantation (the importance of human leukocyte antigen, direct and indirect pathways of antigen recognition, the 3 signals for T-cell activation, and mechanisms and types of allograft rejection) and focus on the mode of action of immunosuppressive drugs that have evolved as the mechanisms and pathways for rejection have been defined through research. This includes recent studies involving the use of costimulatory blockade, regulatory T cells, and tolerance induction that have resulted from research in understanding the mechanisms of immune recognition and function.
Collapse
Affiliation(s)
- K Ravindra
- Duke University Medical Center, Durham, NC, USA
| | | | | | | |
Collapse
|
5
|
Barnett N, Dorling A, Mamode N. B cells in renal transplantation: pathological aspects and therapeutic interventions. Nephrol Dial Transplant 2010; 26:767-74. [PMID: 21139038 DOI: 10.1093/ndt/gfq716] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
B cells are vital in renal transplantation. B2 cells are part of the adaptive immune system. Activated B cells mature into plasma cells or memory B cells: their life spans can be prolonged by niches. B cells have a wide variety of functions: antibody production, antigen presentation, cytokine production and shaping of the splenic architecture. These functions play a vital role in graft rejection, both T cell-mediated rejection and antibody-mediated rejection. Markers of B cell activity include intragraft B cell infiltration, C4d deposition and circulating donor-specific antibodies. Many therapeutic options target B cells or plasma cells. As greater understanding is gained of their appropriate use, and new agents are developed, we should see prolonged graft survival and reduced graft rejection.
Collapse
Affiliation(s)
- Nicholas Barnett
- Renal, Urology and Transplantation Directorate, Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital, London SE1 9RT, UK
| | | | | |
Collapse
|
6
|
Murphey CL, Forsthuber TG. Trends in HLA antibody screening and identification and their role in transplantation. Expert Rev Clin Immunol 2010; 4:391-9. [PMID: 20476928 DOI: 10.1586/1744666x.4.3.391] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
HLA testing has been a staple in transplantation since the recognition that antibodies, directed against lymphocytes, were associated with allograft failure. This seminal finding led to the discovery of the MHC and the appreciation of the importance of HLA testing in transplantation. Early approaches focused on the importance of HLA matching, and were an important aspect of deceased organ donor allocation. More recently, and as a direct result of improvements in immunosuppression, there has been a movement away from 'matching' as the driving force in organ allocation. By contrast, we are now challenged with selecting donor-recipient pairs based on acceptable mismatches. For patients devoid of HLA antibodies, this is not an issue. However, for patients with HLA alloantibodies, that is, the sensitized patient, we face significant challenges in assessing the repertoire of the HLA antibody reactivity they possess. Over the past several years, significant advances in HLA antibody detection have occurred. Solid-phase, multiplex testing platforms have replaced traditional cell-based assays, and have provided better sensitivity and specificity in antibody detection. As a direct result of improved antibody identification, many programs are moving into the realm of the 'virtual crossmatch'. The virtual crossmatch has proven to be successful in renal, cardiac and lung transplantation, and has resulted in a greater percentage of sensitized patients gaining access to transplantation. This review will be devoted to highlighting the latest developments in antibody assessments and discussing their utilization in transplant testing.
Collapse
Affiliation(s)
- Cathi L Murphey
- University of Texas at San Antonio, One UTSA Circle, San Antonio, TX 78249, USA.
| | | |
Collapse
|
7
|
Rangel ÉB, Malheiros DMAC, De Castro MCR, Antunes I, Torres MA, Crescentini F, Genzini T, Perosa M. Antibody-mediated rejection (AMR) after pancreas and pancreas-kidney transplantation. Transpl Int 2009; 23:602-10. [DOI: 10.1111/j.1432-2277.2009.01026.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Expression of the decay-accelerating factor (CD55) in renal transplants--a possible prediction marker of allograft survival. Transplantation 2009; 88:457-64. [PMID: 19696627 DOI: 10.1097/tp.0b013e3181b0517d] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Decay-accelerating factor (CD55) accelerates the decay of C3 and C5 convertases, participating in classical and alternative complement activation pathways. Complement activation plays a major role in antibody-mediated rejection of allografts (AMR); C4d is used as a marker of AMR. Emerging evidence suggests an important role of CD55 in the pathogenesis of AMR. The aim of this study was to investigate the expression of CD55 in renal allografts and to correlate it with the expression of C4d, allograft survival, changes in serum creatinine (SC). METHODS More than 200 renal allograft biopsies, performed for allograft dysfunction, were assessed for peritubular capillary (PTC) C4d and CD55 expression. RESULTS We found significant correlation between changes in SC and PTC CD55 staining pattern in patients with no PTC C4d staining. In these patients, SC increased from baseline by 2.2+0.34, 1.7+0.36, and 0.93+0.24 mg/dL in negative, focal, and diffuse PTC CD55 staining subgroups, respectively. Survival of renal allografts was better in diffuse PTC CD55 staining subgroup than in negative PTC CD55 staining subgroup. CONCLUSIONS These data suggest that CD55 expression has a protective effect on PTC C4d negative renal allografts, and the pattern of PTC CD55 expression may be used as a potential marker of renal allograft survival in patients with no evidence of AMR.
Collapse
|
9
|
Kieran N, Wang X, Perkins J, Davis C, Kendrick E, Bakthavatsalam R, Dunbar N, Warner P, Nelson K, Smith KD, Nicosia RF, Alpers CE, Leca N, Kowalewska J. Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. J Am Soc Nephrol 2009; 20:2260-8. [PMID: 19729438 DOI: 10.1681/asn.2009020199] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
The histologic associations and clinical implications of peritubular capillary C4d staining from long-term renal allografts are unknown. We identified 99 renal transplant patients who underwent an allograft biopsy for renal dysfunction at least 10 yr after transplantation, 25 of whom were C4d-positive and 74 of whom were C4d-negative. The average time of the index biopsy from transplantation was 14 yr in both groups. Compared with C4d-negative patients, C4d-positive patients were younger at transplantation (29 +/- 13 versus 38 +/- 12 yr; P < 0.05) and were more likely to have received an allograft from a living donor (65 versus 35%; P < 0.001). C4d-positive patients had more inflammation, were more likely to have transplant glomerulopathy, and had worse graft outcome. The combined presence of C4d positivity, transplant glomerulopathy, and serum creatinine of >2.3 mg/dl at biopsy were very strong predictors of rapid graft loss. C4d alone did not independently predict graft loss. Retrospective staining of historical samples from C4d-positive patients demonstrated C4d deposition in the majority of cases. In summary, these data show that in long-term renal allografts, peritubular capillary staining for C4d occurs in approximately 25% of biopsies, can persist for many years after transplantation, and strongly predicts graft loss when combined with transplant glomerulopathy.
Collapse
Affiliation(s)
- Niamh Kieran
- Department of Medicine, Division of Nephrology,University of Washington, Seattle, Washington 98195-6521, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, Rike A, Roy-Chaudhury P, Mogilishetty G, Alloway RR, Tevar A, Woodle ES. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9:1063-71. [PMID: 19344434 DOI: 10.1111/j.1600-6143.2009.02577.x] [Citation(s) in RCA: 178] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The effect of de novo DSA detected at the time of acute cellular rejection (ACR) and the response of DSA levels to rejection therapy on renal allograft survival were analyzed. Kidney transplant patients with acute rejection underwent DSA testing at rejection diagnosis with DSA levels quantified using Luminex single-antigen beads. Fifty-two patients experienced acute rejection with 16 (31%) testing positive for de novo DSA. Median follow-up was 27.0 +/- 17.4 months postacute rejection. Univariate analysis of factors influencing allograft survival demonstrated significance for African American race, DGF, cytotoxic PRA >20% (current) and/or >50% (peak), de novo DSA, C4d and repeat transplantation. Multivariate analysis showed only de novo DSA (6.6-fold increased allograft loss risk, p = 0.017) to be significant. Four-year allograft survival was higher with ACR (without DSA) (100%) than mixed acute rejection (ACR with DSA/C4d) (65%) or antibody-mediated rejection (35%) (p < 0.001). Patients with >50% reduction in DSA within 14 days experienced higher allograft survival (p = 0.039). De novo DSAs detected at rejection are associated with reduced allograft survival, but prompt DSA reduction was associated with improved allograft survival. DSA should be considered a potential new end point for rejection therapy.
Collapse
Affiliation(s)
- M J Everly
- Department of Surgery, Transplantation Division, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Perkowska-Ptasińska A, Ciszek M, Chmura A, Galazka Z, Paczek L, Durlik M. Transplant glomerulopathy: clinical and pathological correlations. Transplant Proc 2009; 41:141-9. [PMID: 19249499 DOI: 10.1016/j.transproceed.2008.10.052] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2008] [Accepted: 10/20/2008] [Indexed: 11/17/2022]
Abstract
OBJECTIVE Chronic transplant glomerulopathy (TG) is one of the leading causes of severe posttransplantation proteinuria and graft loss. Our current knowledge about risk factors for the development of TG, as well as factors that affect its dynamics and prognosis, is poor. We sought to describe the pathological and clinical risk factors and correlations of TG as well as parameters that influenced the survival of grafts with that pathology. MATERIALS AND METHODS We retrospectively reevaluated 86 kidney transplant cases with TG that have been recognized on the basis of an indication biopsy since 1997. All TG as well as all pre-TG (previous) biopsies were characterized for the presence of C4d deposits in the graft. RESULTS Younger recipient age and minimal immunosuppression due to drug withdrawal or suboptimal drug doses/blood levels within 3 to 6 months preceding the biopsy were associated with C4d deposition in peritubular capillaries (PTC; P = .0053 and P = .0365, respectively). Diffuse PTC-itis (P = .029, RR [95% confidence interval] = 3.349 [1.131-9.919]) and total interstitial inflammation score (P = .015, RR [95% confidence interval] = 9.662 [1.784-52.329]) were observed to show a negative impact on graft survival. C4d deposition in PTC and glomeruli, the level of pretransplantation sensitization, episodes of acute rejection, and C4d in previous (pre-TG) biopsies did not influence the survival of grafts with TG. CONCLUSIONS Younger recipient age and minimal immunosuppression were associated with C4d positivity in grafts with TG. The survival of kidney grafts with TG was significantly affected by the magnitude of inflammation in the interstitium and PTC, but not by C4d positivity in PTC and glomeruli.
Collapse
Affiliation(s)
- A Perkowska-Ptasińska
- Department of Transplantology and Nephrology, Warsaw Medical University, Warsaw, Poland.
| | | | | | | | | | | |
Collapse
|
12
|
Abstract
BACKGROUND Current antihumoral therapies in transplantation and autoimmune disease do not target the mature antibody-producing plasma cell. Bortezomib is a first in class proteosomal inhibitor, that is Food and Drug Administration approved, for the treatment of plasma cell-derived tumors that is multiple myeloma. We report the first clinical experience with plasma cell-targeted therapy (bortezomib) as an antirejection strategy. METHODS Eight episodes of mixed antibody-mediated rejection (AMR) and acute cellular rejection (ACR) in six transplant recipients were treated with bortezomib at labeled dosing. Monitoring included serial donor-specific antihuman leukocyte antigen antibody (DSA) levels and repeated allograft biopsies. RESULTS Six kidney transplant patients received bortezomib for AMR and concomitant ACR. In each case, bortezomib therapy provided (1) prompt rejection reversal, (2) marked and prolonged reductions in DSA levels, (3) improved renal allograft function, and (4) suppression of recurrent rejection for at least 5 months. Moreover, immunodominant DSA (iDSA) (i.e., the antidonor human leukocyte antigen antibody with the highest levels) levels were decreased by more than 50% within 14 days and remained substantially suppressed for up to 5 months. One or more additional DSA were present at lower concentrations (non-iDSA) in each patient and were also reduced to nondetectable levels. Bortezomib-related toxicities (gastrointestinal toxicity, thrombocytopenia, and paresthesias) were all transient. CONCLUSIONS Bortezomib therapy: (1) provides effective treatment of AMR and ACR with minimal toxicity and (2) provides sustained reduction in iDSA and non-iDSA levels. Bortezomib represents the first effective antihumoral therapy with activity in humans that targets plasma cells.
Collapse
|